Skip to content

Study · Not a test of the peptide alone · 2024

1 result

Acne Keloidalis Nuchae in a Caucasian Non-Hispanic Woman With Metabolic Syndrome and Autoimmune Thyroiditis: A Case Report.

Anatolieva B, Kirov V, Ganeva S

Cureus27 Apr 2024Cited by 1 (Europe PMC)

PMID38803744 (opens in a new tab)PMCIDPMC11128944 (opens in a new tab)DOI10.7759/cureus.59119 (opens in a new tab)PepBankPUB-38803744
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Acne keloidalis nuchae (AKN) is a rare dermatological condition primarily observed in men of African descent. We present a remarkable case of AKN in a 38-year-old Caucasian non-Hispanic woman with metabolic syndrome and autoimmune thyroiditis. After appropriate treatment during the one-year follow-up (including oral antibiotics, insulin sensitizers, levothyroxine, spironolactone and liraglutide), the patient demonstrated a visible reduction in plaque size and improvement of overall symptoms. Importantly, this improvement persisted even in the absence of topical treatment, further supporting the notion that hormonal abnormalities may play a significant role in the pathogenesis of AKN. This case report highlights the potential link between AKN and endocrinologic disorders, such as metabolic syndrome and autoimmune thyroiditis. However, further research is warranted to elucidate the underlying mechanisms and establish the causative relationship. Early recognition, appropriate management of associated conditions, and tailored treatment strategies may lead to better outcomes and improved quality of life.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In a 38-year-old woman with acne keloidalis nuchae, a regimen of oral antibiotics, insulin sensitizers, levothyroxine, spironolactone and liraglutide was followed by smaller plaques and better symptoms over one year.

    In plain wordsIn one woman with a skin condition, a multi-drug regimen that included liraglutide was followed by smaller plaques. The effect of liraglutide alone is unknown.

    Peptide
    Liraglutide
    Outcome
    DecreasePlaque size and symptoms of acne keloidalis nuchae
    Study

    n = 1

    Outcome group
    Skin and hair · Skin and wound

    Source sentences

    Summary
    After appropriate treatment during the one-year follow-up (including oral antibiotics, insulin sensitizers, levothyroxine, spironolactone and liraglutide), the patient demonstrated a visible reduction in plaque size and improvement of overall symptoms.
    1 context sentence
    Summary · context
    We present a remarkable case of AKN in a 38-year-old Caucasian non-Hispanic woman with metabolic syndrome and autoimmune thyroiditis.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.